News | June 23, 2025
Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories India for Rs. 16 Cr
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The change of name has been carried on pursuant to the Scheme of Amalgamation
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
